Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 016580315 approvals104 trials

WHANIN PHARM CO.,LTD

Official website

KOSPI-listed pharma company ranked No.1 in Korea's psychiatric drug market (2024 IMS Data) with neuropsychiatric drugs over 80% of revenue.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1982 and listed on the KOSPI in 1996, Whanin Pharm is a pharmaceutical company specializing in neuropsychiatric drugs. It in-licenses the antidepressant Argotin, the anticonvulsant Zebinix, and the neuropsychiatric drug Clozaril from Servier (France), Bial Portela (Portugal), and Viatris (US) respectively, under 2017-2018 contracts, and distributes them exclusively in Korea. Neuropsychiatric drugs account for over 80% of total revenue, and per 2024 IMS Data the company ranks No.1 in Korea's psychiatric drug market; it is also developing the improved new drugs WIL-1901 (Alzheimer's, market size KRW 316.9bn) and WIP-2401 (depression, KRW 250bn), and the generics WIE-2301/WIE-2302 (essential hypertension, KRW 1.2tn each), WIE-2303 (peptic ulcer, KRW 1,266.6bn), and WIG-2202 (epilepsy, KRW 340bn, approval completed).

Products & technology

  • Argotin (antidepressant)Antidepressant, exclusively distributed in Korea (in-licensed from Servier, France)
  • Zebinix (anticonvulsant)Anticonvulsant, exclusively distributed in Korea (in-licensed from Bial Portela, Portugal)
  • Clozaril (neuropsychiatric drug)Neuropsychiatric drug, exclusively distributed in Korea (in-licensed from Viatris, US)

Regulatory approvals

data.go.kr

315 Korean MFDS drug approvals · 1960–2026

  • MFDS drugWhanIn Atomoxetine Tab. 60mg2026-03-12
    Drug · Prescription · Approval202600750
  • MFDS drugWhanIn Atomoxetine Tab. 80mg2026-02-24
    Drug · Prescription · Approval202600515
  • MFDS drugWhanIn Atomoxetine Tab. 10mg2026-02-10
    Drug · Prescription · Approval202600373
  • MFDS drugWhanIn Atomoxetine Tab. 18mg2026-02-10
    Drug · Prescription · Approval202600374
  • MFDS drugWhanIn Atomoxetine Tab. 25mg2026-02-10
    Drug · Prescription · Approval202600375
  • MFDS drugWhanIn Atomoxetine Tab. 40mg2026-01-07
    Drug · Prescription · Approval202600050
  • MFDS drugTofaciz Tab. 10mg2025-11-24
    Drug · Prescription · Approval202503050
  • MFDS drugBriva Tab. 75mg2025-11-12
    Drug · Prescription · Approval202502931
  • MFDS drugBriva Tab. 100mg2025-09-19
    Drug · Prescription · Approval202502489
  • MFDS drugBriva Tab. 50mg2025-09-19
    Drug · Prescription · Approval202502490
  • MFDS drugBriva Tab. 10mg2025-09-19
    Drug · Prescription · Approval202502491
  • MFDS drugBriva Tab. 25mg2025-09-19
    Drug · Prescription · Approval202502492
Show 68 more
  • MFDS drugOfenib Tab. 100mg2025-05-07
    Drug · Prescription · Approval202501106
  • MFDS drugOfenib Tab. 150mg2025-05-07
    Drug · Prescription · Approval202501107
  • MFDS drug.2025-03-17
    Drug · OTC · Notification202500581
  • MFDS drugWhanIn Memantine Tab. 5mg2025-02-03
    Drug · Prescription · Approval202500214
  • MFDS drugArgotin Tab. 25mg2024-12-26
    Drug · Prescription · Approval202403080
  • MFDS drug환인아질사르탄정80밀리그램(아질사르탄메독소밀칼륨)(수출용)2024-12-24
    Drug · Prescription · Approval202403072
  • MFDS drug환인아질사르탄정40밀리그램(아질사르탄메독소밀칼륨)(수출용)2024-12-24
    Drug · Prescription · Approval202403073
  • MFDS drug환인아질사르탄정20밀리그램(아질사르탄메독소밀칼륨)(수출용)2024-12-24
    Drug · Prescription · Approval202403074
  • MFDS drugDomentia Tab. 10/20mg2024-12-23
    Drug · Prescription · Approval202403047
  • MFDS drugWhanIn Quetapine XR Tab. 50mg2024-09-27
    Drug · Prescription · Approval202402325
  • MFDS drugNiceon tab. 10mg2024-06-19
    Drug · Prescription · Approval202401478
  • MFDS drugWhanIn Memantine Tab. 20mg2024-04-30
    Drug · Prescription · Approval202401044
  • MFDS drugWhanIn Memantine OD Tab. 20mg2024-04-24
    Drug · Prescription · Approval202400958
  • MFDS drugPosarina Tab, 10/5mg2024-04-22
    Drug · Prescription · Approval202400922
  • MFDS drug.2024-03-21
    Drug · Prescription · Approval202400581
  • MFDS drugNiceon tab. 30mg2023-12-14
    Drug · Prescription · Approval202303346
  • MFDS drugVortive Tab. 20mg (Vortioxetine Hydrobromide)2023-05-12
    Drug · Prescription · Approval202301537
  • MFDS drugVortive Tab. 10mg (Vortioxetine Hydrobromide)2023-05-12
    Drug · Prescription · Approval202301538
  • MFDS drugVortive Tab. 5mg (Vortioxetine Hydrobromide)2023-05-12
    Drug · Prescription · Approval202301539
  • MFDS drugPeranel Tab. 10mg2023-03-03
    Drug · Prescription · Approval202300746
  • MFDS drugPeranel Tab. 8mg2023-03-03
    Drug · Prescription · Approval202300747
  • MFDS drugPeranel Tab. 4mg2023-03-03
    Drug · Prescription · Approval202300748
  • MFDS drugDukaforge Tab. 60/5mg2023-01-06
    Drug · Prescription · Approval202300107
  • MFDS drugDukaforge Tab. 60/2.5mg2023-01-06
    Drug · Prescription · Approval202300128
  • MFDS drugDukaforge Tab. 30/2.5mg2023-01-06
    Drug · Prescription · Approval202300135
  • MFDS drugWhanin Sertraline Tab. 25mg (Sertraline Hydrochloride)2022-11-29
    Drug · Prescription · Approval202204286
  • MFDS drugAripizole Tab. 1mg2022-11-09
    Drug · Prescription · Approval202204039
  • MFDS drugAlpram Tab. 0.125mg2022-10-26
    Drug · Prescription · Approval202203919
  • MFDS drugFenacsone Tab.2022-09-22
    Drug · Prescription · Approval202203633
  • MFDS drugWe-ase Tab.2022-05-31
    Drug · OTC · Notification202202291
  • MFDS drugPeranel Tab. 12mg2022-04-19
    Drug · Prescription · Approval202201598
  • MFDS drugPeranel Tab. 6mg2022-04-19
    Drug · Prescription · Approval202201599
  • MFDS drugPeranel Tab. 2mg2022-04-19
    Drug · Prescription · Approval202201600
  • MFDS drugTofaciz Tab. 5mg2022-04-18
    Drug · Prescription · Approval202201584
  • MFDS drugPosarin Tab. 5mg2022-03-15
    Drug · Prescription · Approval202201074
  • MFDS drugDefaxine SR Tab. 25mg2022-01-28
    Drug · Prescription · Approval202200501
  • MFDS drugPosarin Tab. 10mg2022-01-27
    Drug · Prescription · Approval202200440
  • MFDS drugRabemore Tab. 20/500mg2022-01-27
    Drug · Prescription · Approval202200470
  • MFDS drugPosarin Plus Tab. 10/100mg2022-01-12
    Drug · Prescription · Approval202200211
  • MFDS drugRabemore Tab. 10/500mg2021-12-31
    Drug · Prescription · Approval202108209
  • MFDS drugJaroban Tab. 2.5mg2021-12-29
    Drug · Prescription · Approval202108133
  • MFDS drugWhanIn Pitavastatin Tab. 4mg2021-07-01
    Drug · Prescription · Approval202105021
  • MFDS drugWhanIn Pitavastatin Tab. 1mg2021-07-01
    Drug · Prescription · Approval202105022
  • MFDS drugWhanIn Pitavastatin Tab. 2mg2021-07-01
    Drug · Prescription · Approval202105023
  • MFDS drugStadron Inj. 5mg/100mL2021-06-29
    Drug · Prescription · Approval202104919
  • MFDS drugJaroban Tab. 20mg2021-04-22
    Drug · Prescription · Approval202103338
  • MFDS drugJaroban Tab. 15mg2021-04-22
    Drug · Prescription · Approval202103339
  • MFDS drugJaroban Tab. 10mg2021-04-22
    Drug · Prescription · Approval202103340
  • MFDS drugRamipexol ER Tab. 1.5mgRevoked2021-04-20
    Drug · Prescription · Approval202103199
  • MFDS drugRamipexol ER Tab. 0.75mgRevoked2021-04-20
    Drug · Prescription · Approval202103200
  • MFDS drugRamipexol Tab. 1.0mgRevoked2021-03-11
    Drug · Prescription · Approval202102240
  • MFDS drugRamipexol Tab. 0.5mgRevoked2021-03-11
    Drug · Prescription · Approval202102241
  • MFDS drugRamipexol Tab. 0.125mgRevoked2021-03-11
    Drug · Prescription · Approval202102242
  • MFDS drugBemiga SR Tab. 50mg2021-02-18
    Drug · Prescription · Approval202101444
  • MFDS drugCombizet Tab. 10/40mg2021-02-18
    Drug · Prescription · Approval202101513
  • MFDS drugCombizet Tab. 10/20mg2021-02-18
    Drug · Prescription · Approval202101514
  • MFDS drugCombizet Tab. 10/10mg2021-02-18
    Drug · Prescription · Approval202101515
  • MFDS drugMirzentac OD Tab. 7.5mg2020-12-31
    Drug · Prescription · Approval202009438
  • MFDS drugMirzentac OD Tab. 30mg2020-12-24
    Drug · Prescription · Approval202009229
  • MFDS drugMirzentac OD Tab. 15mg2020-12-07
    Drug · Prescription · Approval202008509
  • MFDS drugRamipexol ER Tab. 0.375mgRevoked2020-11-19
    Drug · Prescription · Approval202008000
  • MFDS drugZebinix Tab. 200mg2020-11-10
    Drug · Prescription · Approval202007717
  • MFDS drugZebinix Tab. 800mg2020-11-10
    Drug · Prescription · Approval202007718
  • MFDS drugZebinix Tab. 400mg2020-11-10
    Drug · Prescription · Approval202007719
  • MFDS drugZebinix Tab. 600mg2020-11-10
    Drug · Prescription · Approval202007720
  • MFDS drugCerazin Inj.2020-10-30
    Drug · Prescription · Notification202007461
  • MFDS drugZopita Tab. 1mgRevoked2020-10-14
    Drug · Prescription · Approval202007054
  • MFDS drugZopita Tab. 2mgRevoked2020-10-14
    Drug · Prescription · Approval202007055

Showing the 80 most recent of 315 records.

Clinical trials

data.go.kr

104 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 91 · Phase 1 8 · Phase 2 3 · Phase 3 2)

  • Phase 1WIL-19012026-06-22

    2 trial sites

  • BioequivalenceWIG-25082026-06-02

    2 trial sites

  • BioequivalenceWIG-25082026-06-02

    2 trial sites

  • BioequivalenceWIG-25042026-05-12

    2 trial sites

  • BioequivalenceWIG-25052026-03-13

    2 trial sites

  • BioequivalenceWIG-2503-402026-03-12

    2 trial sites

  • BioequivalenceWIG-2503-102026-03-12

    2 trial sites

  • BioequivalenceWIG-25092026-03-03

    2 trial sites

  • BioequivalenceWIG-25092026-03-03

    2 trial sites

  • BioequivalenceWIG-25072026-02-06

    2 trial sites

  • Phase 1WIP-24012025-09-09

    2 trial sites

  • BioequivalenceWIG-23012025-07-07

    2 trial sites

Show 68 more
  • Phase 1WIG-2401-802025-03-11

    2 trial sites

  • BioequivalenceWIG-22022025-01-09

    2 trial sites

  • Phase 1WIG-24012025-01-07

    2 trial sites

  • Phase 1WIG-24032024-07-02

    2 trial sites

  • BioequivalenceWIG-23042024-04-18

    2 trial sites

  • BioequivalenceWIM-2301B2024-02-19

    2 trial sites

  • BioequivalenceWIM-2301B2024-02-19

    2 trial sites

  • BioequivalenceWIM-2101D2024-02-08

    2 trial sites

  • BioequivalenceWIG-QX152023-06-28

    2 trial sites

  • BioequivalenceWIG-QX152023-03-21

    2 trial sites

  • BioequivalenceWIG-QX152023-03-21

    2 trial sites

  • BioequivalenceWIG-22032022-10-07

    2 trial sites

  • BioequivalenceWIG-2102B2022-03-23

    2 trial sites

  • BioequivalenceWIG-2102B2022-03-17

    2 trial sites

  • BioequivalenceWIG-19032022-02-15

    2 trial sites

  • BioequivalenceWIG-19032022-02-15

    2 trial sites

  • BioequivalenceWIG-21062022-01-24

    2 trial sites

  • BioequivalenceWIM-2101A2021-12-28

    2 trial sites

  • BioequivalenceWIM-2101D2021-12-28

    2 trial sites

  • BioequivalenceWIM-2101D2021-12-28

    2 trial sites

  • BioequivalenceWIM-2101A2021-12-28

    2 trial sites

  • BioequivalenceWIE-1904TS2021-12-28

    2 trial sites

  • BioequivalenceWIG-21052021-12-10

    2 trial sites

  • BioequivalenceWIG-21072021-12-06

    2 trial sites

  • BioequivalenceWIG-20022021-12-01

    2 trial sites

  • Phase 3WID-RGC202021-04-16

    26 trial sites

  • Bioequivalence데팍신서방정2021-04-08

    2 trial sites

  • Bioequivalence데팍신서방정2021-04-07

    2 trial sites

  • BioequivalenceWIG-19032021-03-23

    2 trial sites

  • BioequivalenceWIG-19032021-03-23

    2 trial sites

  • BioequivalenceWIG-QX152021-02-26

    2 trial sites

  • BioequivalenceWIG-QX152021-02-26

    2 trial sites

  • BioequivalenceWIM-2301B2021-02-16

    2 trial sites

  • BioequivalenceWIM-2301B2021-02-16

    2 trial sites

  • Bioequivalence페라넬정6밀리그램2020-05-08

    2 trial sites

  • BioequivalenceWIG-QX152020-03-02

    2 trial sites

  • BioequivalenceWIG-QX152020-03-02

    2 trial sites

  • BioequivalenceWIM-2301B2020-02-07

    2 trial sites

  • BioequivalenceWIM-2301B2020-02-06

    2 trial sites

  • Bioequivalence라미펙솔서방정0.375밀리그램(프라미펙솔염산염일수화물)2019-09-19

    2 trial sites

  • Bioequivalence라미펙솔서방정0.375밀리그램(프라미펙솔염산염일수화물)2019-09-18

    2 trial sites

  • Bioequivalence라미펙솔정0.25밀리그램(프라미펙솔염산염일수화물)2019-09-18

    2 trial sites

  • BioequivalenceWIG-QX152019-07-05

    2 trial sites

  • BioequivalenceWIG-QX152019-07-05

    2 trial sites

  • Phase 1WID-ESL182019-07-03

    2 trial sites

  • Bioequivalence클로자릴정100밀리그램(클로자핀)2019-06-03

    14 trial sites

  • Bioequivalence팔페리돈서방캡슐6밀리그램(팔리페리돈)2019-05-21

    2 trial sites

  • Bioequivalence팔페리돈서방캡슐6밀리그램(팔리페리돈)2019-05-20

    2 trial sites

  • Phase 3WIP-RVX142019-03-11

    1 trial site

  • Phase 1WIP-DF172019-02-25

    2 trial sites

  • Phase 1WIP-DF172019-01-30

    2 trial sites

  • Bioequivalence미르젠탁오디정15밀리그램(미르타자핀)2018-10-30

    2 trial sites

  • Bioequivalence라사핀정(라사길린메실산염)2018-10-22

    1 trial site

  • Bioequivalence로나큐정8밀리그램(블로난세린)2018-03-14

    2 trial sites

  • Bioequivalence멜서타서방캡슐27밀리그램(메틸페니데이트염산염)2018-02-22

    2 trial sites

  • Bioequivalence케프렙톨서방정500밀리그램(레비티라세탐)2017-11-21

    2 trial sites

  • Bioequivalence케프렙톨서방정750밀리그램(레비티라세탐)2017-11-21

    2 trial sites

  • Bioequivalence환인두타스테리드정 0.5 밀리그램(가칭)2017-09-22

    2 trial sites

  • BioequivalenceWIG-QX152017-06-13

    2 trial sites

  • Bioequivalence환인쿠에티아핀서방정200밀리그램(가칭)2017-06-13

    2 trial sites

  • Bioequivalence환인미르타자핀오디정15 밀리그램(미르타자핀)(가칭)2017-02-03

    2 trial sites

  • Bioequivalence환인미르타자핀정15밀리그램(미르타자핀)(가칭)2017-02-03

    2 trial sites

  • Bioequivalence환인메만틴오디정10밀리그램2016-07-18

    2 trial sites

  • Bioequivalence쿠에타핀정12.5밀리그램(쿠에티아핀푸마르산염)2016-06-16

    2 trial sites

  • Bioequivalence네오마찐정100밀리그램(클로르프로마진염산염)2015-12-29

    2 trial sites

  • Bioequivalence환인탄산리튬정2015-12-03

    2 trial sites

  • Bioequivalence리버티정10밀리그램(변경 후)(클로르디아제폭시드염산염)2015-12-03

    2 trial sites

  • Bioequivalence환인트라조돈염산염캡슐2015-11-27

    2 trial sites

Showing the 80 most recent of 104 records.

R&D and key agreements

Source: DART corporate disclosure

WIL-1901 · 알츠하이머병 · GMP 생산 · Improved new drug; indication market size KRW 316.9bn

WIP-2401 · 우울증 · 생동 · Improved new drug; indication market size KRW 250bn

WIE-2301 · 본태성고혈압 · 생동 · Generic; indication market size KRW 1.2tn

WIE-2302 · 본태성고혈압 · 제제연구 · Generic; indication market size KRW 1.2tn

WIE-2303 · 위궤양 · Pilot PK · Generic; indication market size KRW 1,266.6bn

WIG-2202 · 뇌전증 · 허가 완료 · Generic; indication market size KRW 340bn

Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

HL GENOMICS Co., Ltd.85
Kolmar BioTech, Inc.85

Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition